

RESEARCH OPPORTUNITY

NAMI is committed to ensuring that the most effective treatments for mental illness are available to those who need them. Determining which treatments are most effective requires research. When NAMI is approached to be involved in research of any type, at any level, we take it very seriously. NAMI's Chief Medical Officer Dr. Ken Duckworth and Chief Program Officer Dr. Teri Brister thoroughly review the research protocols and methodology and the documentation that the study has been approved by an Institutional Review Board (IRB) to assure the safety of those involved.

NAMI does not accept financial compensation for recruiting clinical trial participants. NAMI also does not endorse any products or treatments. We share these research opportunity notices with you, our field leaders, to distribute at your discretion if you believe that members of your community may be interested in participating in these trials.

If you have questions about research at NAMI, please visit [NAMI.org/research](https://www.nami.org/research) or email us at research@nami.org.

WHAT IS THE STUDY?

This study is a clinical research trial* of an investigational medication (study medicine) for depression that is designed to work differently than currently available antidepressants. The trial will determine if the study medicine is safe and effective for improving symptoms of depression, including anhedonia, which is having less interest or pleasure in things you used to enjoy. Participants will be randomly assigned to receive the once-daily, oral study medicine or placebo over the course of 6 weeks. Total participation time, including screening, treatment, and follow-up, is up to 16 weeks. If participants complete the treatment period, they may have the option to participate in a year-long study where all participants receive the study medicine. Reimbursement for study-related expenses and other compensation may be available. The goal of this study is to increase treatment options available for people experiencing depression.

**Participants will join 1 of 3 individual clinical trials that are all part of the same clinical research program.*

WHO CAN PARTICIPATE?

Individuals may be eligible for this study if they:

- Are 18-65 years old
- Have been told by a doctor that they have depression (also known as major depressive disorder or MDD)
- Have had symptoms of depression for 1-12 months
- Are not pregnant or breastfeeding
- Can give consent and follow study instructions

There will be 332 people participating in each clinical trial within the clinical research program.

WHERE IS THE STUDY TAKING PLACE?

Each clinical trial takes place either in the U.S. only or in the U.S. and internationally. To be directed to the clinical trial location closest to you, visit the research program website below.

HOW DO I LEARN MORE?

The research program brochure and poster include additional information. If you have questions, would like more information, or are interested in participating, please visit <https://koastalstudy.com/>.